Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 8/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 3/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4236769 | 0.99 | HTR3A (0.38) | HTR3AADRB2NCF1NR4A2MALT1 | |
| SCHEMBL4240352 | 0.90 | CAPN1 (0.39) | ADRB2NCF1MALT1MEN1KMT2A | |
| SCHEMBL4240969 | 0.89 | MALT1 (0.38) | MALT1ROCK1NTSR1 | |
| SCHEMBL4241847 | 0.89 | PTGDR2 (0.41) | HTR3AMALT1KMT2AF10NTSR1 | |
| SCHEMBL4244710 | 0.89 | NTSR1 (0.39) | MALT1MEN1KMT2ANTSR1 | |
| SCHEMBL4240870 | 0.89 | ROCK1 (0.37) | HTR3AMALT1ROCK1F10 | |
| SCHEMBL4245169 | 0.89 | MALT1 (0.37) | ADRB2NCF1MALT1ROCK1NTSR1 | |
| SCHEMBL4242997 | 0.89 | MALT1 (0.37) | ADRB2NCF1MALT1ROCK1NTSR1 | |
| SCHEMBL4244642 | 0.89 | NTSR1 (0.43) | ADRB2NCF1MEN1KMT2ANTSR1 | |
| SCHEMBL4241610 | 0.89 | ROCK1 (0.39) | HTR3ANR4A2MALT1ROCK1NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531663-B2 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-12 | — | — | US | claimed |
| US-20050026989-A1 | 3-Guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | claimed |
| US-7531663-B2 | 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-20050026989-A1 | 3-Guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026989-A1 | 3-Guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them | IDO1, IDO2, HTR3C | HTR3A 7/4885ADRB2 19/4885NCF1 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.